


# Cancer Molecular Therapeutics Research Association (CMTRA) Conference 2024



Register at:



**Sunday-Thursday, July 14<sup>th</sup>-18<sup>th</sup> 2024**  
**Granlibakken Lake Tahoe Resort, CA**



# Cancer Molecular Therapeutics Research Association (CMTRA) Conference, Granlibakken Lake Tahoe Resort, CA, July 14-18, 2024

<https://www.cancermolecularterapeutics.org/>

## Keynote Speakers:

Alan Ashworth (UCSF)

Marcia Haigis (Harvard)

## AI/Machine Learning in R&D:

Pat Walters (Relay Therapeutics)

Lingle Wang (Schrodinger Inc.)

## Chemical Biology in Oncology:

Gerry Crabtree (Stanford)

Ben Cravatt (Scripps Inst.)

Michelle Arkin (UCSF)

## Radioligand Cancer Therapies:

Markus Reschke (Novartis Inc)

Michael Evans (UCSF)

Anna Wu (City of Hope)

## Synthetic Lethality:

Peter Olson (Mirati Therapeutics)

Matt Patricelli (Vividion Therapeutics)

## Prostate Cancer:

Melissa Junttila (ORIC Pharmaceuticals)

Amina Zubeidi (Univ. British Columbia)

David Quigley (UC San Francisco)

Mark Rolfe (Bristol Myers Squibb)

## Lineage Infidelity in Cancer:

Laura Attardi (Stanford)

Rosie Sears (OHSU)

**Panel Discussion/Q&A: “Future Challenges in Cancer Research & Drug Development”**  
with leading voices from academia, biotech and the pharmaceutical industry

# Cancer Molecular Therapeutics Research Association (CMTRA) Annual Conference 2024

July 14-18th, 2024  
Schedule and Program:

## Sunday, July 14<sup>th</sup> 2024: Granlibakken GRANHALL

4:00PM	Arrival & Check-In
6:00-7:00PM	Dinner at Cedar House
7:30-7:45PM	<p><b>Welcome &amp; Introduction</b>  <b>Martin McMahon, PhD</b>  Huntsman Cancer Institute &amp; Dept. of Dermatology,  University of Utah, Salt Lake City, Utah  <b>President CMTRA</b></p>
7:45-8:45PM	<p><b>KEYNOTE SPEAKER:</b>  <b>Marcia Haigis, PhD</b>  Professor, Department of Cell Biology, Harvard Medical School  <i>"The Role of Metabolites in Cancer, Immunity and Aging"</i></p>
9:00PM	Welcome Reception

## Monday, July 15<sup>th</sup> 2024: MORNING

7:30-8:15AM	Breakfast
8:30AM-12:30PM	<p><b>MORNING SESSION: Prostate Cancer</b>  <b>GRANHALL</b>  <b>Discussion Leader: Lori Friedman, PhD</b>  Chief Scientific Officer of ORIC Pharmaceuticals; Vice-President CMTRA</p>
8:30-8:40AM	Introduction
8:40-9:10AM	<p><b>Amina Zoubeidi, PhD</b>  Canada Research Chair in Cancer Therapy Resistance &amp; Professor,  University of British Columbia  <i>"Lineage Plasticity in Prostate Cancer: From Biology to Therapy"</i></p>
9:10-9:30AM	Discussion
9:30-10:00AM	<p><b>Melissa Junttila, PhD</b>  Vice President, Head of Biology at ORIC Pharmaceuticals  <i>"The Fate of Prostate Cancer Cells Treated with PRC2 Inhibitors Underlies Combination Synergy Observe with AR Pathway Inhibitors"</i></p>
10:00-10:20AM	Discussion
10:20-10:40AM	Coffee Break
10:40-11:10AM	<p><b>David Quigley, PhD</b>  Assistant Professor, Dept. of Urology, UC San Francisco,  <i>"Genomic And Epigenomic Mechanisms of Targeted Therapy Resistance in Prostate Cancer"</i></p>

11:10-11:30AM	<b>Discussion</b>
11:30AM-Noon	<p><b>Mark Rolfe, PhD</b> Senior Vice President, Research Oncogenesis Thematic Research Center, Bristol Myers Squibb</p> <p><i>"Discovery of BMS-986365 a Ligand-Directed Androgen Receptor Degradar with a Dual Mechanism-of-Action and Potential for the Treatment of Advanced Prostate Cancer"</i></p>
Noon-12:20PM	<b>Discussion</b>
12:30-1:30PM	<b>Lunch</b>
1:30-4:45PM	<p><b>OPEN NETWORKING AFTERNOON</b> See activities handout</p>
5:00-6:30PM	<b>Poster Session and Social</b>
6:30-7:30PM	<b>Dinner</b>
<b>Monday, July 15<sup>th</sup> 2024: EVENING</b>	
7:30-9:45PM	<p><b>EVENING SESSION: Artificial Intelligence/Machine Learning in Oncology R&amp;D</b></p> <p><b>Discussion Leader: Eli Wallace, PhD</b> Chief Scientific Officer BridgeBio; Secretary CMTRA</p>
7:30-7:45PM	<b>Introduction</b>
7:45-8:15PM	<p><b>Pat Walters, PhD</b> Chief Data Officer at Relay Therapeutics</p> <p><i>"Artificial Intelligence in Drug Discovery – Revolution, Evolution, or Complete Nonsense"</i></p>
8:15-8:45PM	<b>Discussion</b>
8:45-9:15PM	<p><b>Lingle Wang, PhD</b> Vice President, Scientific Development at Schrodinger, Inc.</p> <p><i>"Accelerating Drug Discovery with Digital Chemistry: When Physics meets AI"</i></p>
9:15-9:45PM	<b>Discussion</b>
9:45PM	<b>Social</b>
<b>Tuesday, July 16<sup>th</sup> 2024, MORNING</b>	
7:30-8:15AM	<b>Breakfast</b>
8:30AM-Noon	<p><b>MORNING SESSION: Chemical Biology in Oncology</b> <b>Discussion Leader: Bob Abraham, PhD</b></p>



8:30-8:45AM	<b>Introduction</b>
8:45-9:15AM	<b>Gerry Crabtree, MD</b> Professor of Pathology & Developmental Biology, Stanford University & HHMI Investigator <i>“Rewiring Cancer Drivers to Activate Pathways of Programmed Cell Death”</i>
9:15-9:40AM	<b>Discussion</b>
9:40-10:00AM	<b><u>Group Photograph and Coffee Break</u></b>
10:00–10:30AM	<b>Ben Cravatt, PhD</b> Professor, Norton B. Gilula Chair in Biology and Chemistry, Scripps Institute <i>“Activity-Based Proteomics – Cancer Target and Ligand Discovery on a Global Scale”</i>
10:30-11:00AM	<b>Discussion</b>
11:00-11:30AM	<b>Michelle Arkin, PhD</b> Professor and Chair, Pharmaceutical Chemistry & Executive Director, Small Molecule Discovery Center, U.C. San Francisco <i>“Stabilizing Chaperone/Client Interactions as an Alternative Approach To Cancer Drug Discovery”</i>
11:30-Noon	<b>Discussion</b>
12:00-1:00PM	<b>Lunch</b>
1:00-4:45PM	<b>OPEN NETWORKING AFTERNOON</b>
5:00-6:30PM	<b>Poster Session and Social</b>
<b>Tuesday, July 16<sup>th</sup> 2024: EVENING</b>	
7:30-9:45PM	<b>EVENING SESSION: Lineage Infidelity in Cancer</b> Discussion Leader: Aria Vaishnavi, PhD
7:30-7:45PM	<b>Introduction</b>
7:45-8:15PM	<b>Laura Attardi, PhD</b> Professor, Dept. of Radiation Oncology, Stanford University <i>“Deciphering How TP53 Governs Cell State Transitions in Lung and Pancreatic Cancer”</i>
8:15-8:45PM	<b>Discussion</b>
8:45-9:15PM	<b>Rosalie Sears, PhD</b> Professor of Molecular and Medical Genetics, School of Medicine Co-Director, Brenden-Colson Center for Pancreatic Care, School of Medicine Krista L. Lake Chair in Cancer Research

	<b><i>“Aggressive Phenotypes and Therapeutic Targets in Liver Metastatic Pancreatic Cancer”</i></b>
9:15-9:40PM	Discussion
9:40PM	Social
<b>Wednesday, July 17<sup>th</sup> 2024</b>	
7:30-8:15AM	Breakfast
8:30AM-12:00PM	<b>MORNING SESSION: Targeted Biologic Radio-Ligand Therapy</b> Discussion Leader: Markus Reschke, PhD
8:30-8:45AM	Introduction
8:45-9:15AM	<b>Markus Reschke, PhD</b> Executive Director, Head of RLT Drug Discovery, Novartis Biomedical Research Oncology <b><i>“The Radioligand Therapy Platform at Novartis: Challenges and Opportunities”</i></b>
9:15-9:40AM	Discussion
9:40-10:00AM	Coffee Break
10:00-10:30AM	<b>Mike Evans, PhD</b> Professor, Dept. of Radiology & Biomedical Imaging, U.C. San Francisco. <b><i>“Applying Chemical Biology to Maximize the Antitumor Effects of Targeted Radiotherapies”</i></b>
10:30-10:55AM	Discussion
11:00-11:30AM	<b>Anna Wu, PhD</b> Chair and Professor, Department of Immunology & Theranostics, City of Hope, <b><i>“Engineered Antibody Fragments Targeting PSCA For Radio-Ligand Therapy of Pancreatic and Prostate Cancer”</i></b>
11:30-11:55AM	Discussion
Noon-1:30PM	Lunch
1:30-2:30PM	<b>Panel Discussion – Voices from academia, industry and venture capital on the current state and future of oncology research, drug discovery and development</b> Discussion Leader: Eli Wallace, PhD
2:30-3:00PM	Coffee Break
3:00-5:00PM	<b>AFTERNOON SESSION: Synthetic Lethality</b> Discussion Leader: Emma Lees, PhD

3:00-3:15PM	<b>Introduction</b>
3:15-3:45PM	<p><b>Pete Olson, PhD</b>  Vice President of Research, Bristol Myers Squibb  <i>“Exploiting Synthetic Lethality to Develop a Precision Medicine for CDKN2A/MTAP-deleted Cancers Using an MTA-cooperative PRMT5 Inhibitor”</i></p>
3:45-4:10PM	<b>Discussion</b>
4:10–4:40PM	<p><b>Matt Patricelli, PhD</b>  Chief Scientific Officer, Vividion Therapeutics  <i>“Chemoproteomic Discovery of a Covalent Allosteric Inhibitor of WRN Helicase”</i></p>
4:40-5:10PM	<b>Discussion</b>
6:00-7:00PM	<b>Dinner</b>
7:15-8:15PM	<p><b>KEYNOTE SPEAKER:</b>  <b>Alan Ashworth, PhD</b>  President, Helen Diller Family Comprehensive Cancer Center Senior &amp; E. Dixon Heise Distinguished Professor in Oncology, U.C. San Francisco  <i>“Synthetic Lethal and Combinatorial Approaches to Cancer Therapy”</i></p>
8:30-10:00PM	<b>Farewell Reception</b>
<b>Thursday, July 18<sup>th</sup> 2024</b>	
11:00AM	<b>Check out by 11:00AM</b>
<p><b>IMPORTANT NOTICE:</b> By attending this conference, you agree to respect the confidentiality of the proceedings. Specifically, photographing or recording of sessions, posters or discussions is not permitted. Reference to material presented or discussed may not be included in any publication. Permission to cite information may subsequently be obtained directly from the presenter and is beyond the control of the meeting organizers.</p>	
<p><b>THIS MEETING WOULD NOT BE POSSIBLE WITHOUT THE GENEROUS CONTRIBUTIONS FROM OUR MANY FRIENDS AND COLLEAGUES</b></p>	
<p><b>CANCER MOLECULAR THERAPEUTICS RESEARCH ASSOCIATION (CMTRA), ANNUAL CONFERENCE 2024</b></p>	